• EDWARD J. BENZ, JR. (Chair), President and Chief Executive Officer Emeritus, Dana-Farber Cancer Institute; and Richard and Susan Smith Distinguished Professor of Medicine, Genetics and Pediatrics, Harvard Medical School
• PETER C. ADAMSON, Global Head, Oncology Development and Pediatric Innovation, Sanofi
• GARNET L. ANDERSON, Senior Vice President and Director, Public Health Sciences Division, Fred Hutchinson Cancer Research Center; and Affiliate Professor, Department of Biostatistics, University of Washington
• KAREN BASEN-ENGQUIST, Annie Laurie Howard Research Distinguished Professor, Professor of Behavioral Science; and Director, Center for Energy Balance in Cancer Prevention and Survivorship, The University of Texas MD Anderson Cancer Center
• SMITA BHATIA, Professor and Vice Chair of Outcomes for Pediatrics; Gay and Bew White Endowed Chair in Pediatric Oncology; Director, Institute for Cancer Outcomes and Survivorship; and Associate Director for Outcomes Research, Comprehensive Cancer Center, The University of Alabama at Birmingham
• CHRIS BOSHOFF, Chief Development Officer, Oncology, Global Product Development, Pfizer Inc.
• CATHY J. BRADLEY, David F. and Margaret Turley Grohne Chair for Cancer Prevention and Control Research; Professor and Associate Dean for Research, Colorado School of Public Health; and Deputy Director, University of Colorado Cancer Center
• OTIS W. BRAWLEY, Bloomberg Distinguished Professor, Department of Epidemiology, Bloomberg School of Public Health, Department of Oncology, School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
• CYNTHIA BROGDON, Head, U.S. Oncology Portfolio Strategy, Bristol-Myers Squibb
• WILLIAM G. CANCE, Chief Medical and Scientific Officer, American Cancer Society
• ROBERT W. CARLSON, Chief Executive Officer, National Comprehensive Cancer Network
• CHRISTINA CHAPMAN, Assistant Professor of Radiation Oncology, University of Michigan
• GWEN DARIEN, Executive Vice President, Patient Advocacy and Engagement, National Patient Advocate Foundation
• NANCY E. DAVIDSON, President and Executive Director, Seattle Cancer Care Alliance; Raisebeck Endowed Chair for Collaborative Research, Senior Vice President, Director, and Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, and Head, Department of Medicine, Division of Medical Oncology, University of Washington
• JAMES H. DOROSHOW, Director, Division of Cancer Treatment and Diagnosis; Deputy Director for Clinical and Translational Research; and Head, Oxidative Signaling and Molecular Therapeutics Group, National Cancer Institute
• NICOLE F. DOWLING, Associate Director for Science, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention
• SCOT W. EBBINGHAUS, Vice President and Therapeutic Area Head, Oncology Clinical Research, Merck Research Laboratories
• KOJO S. J. ELENITOBA-JOHNSON, Professor, Perelman School of Medicine; and Director, Center for Personalized Diagnostics and Division of Precision and Computational Diagnostics, University of Pennsylvania
• STANTON L. GERSON, Director, Case Comprehensive Cancer Center; Interim Dean and Senior Vice President, Medical Affairs, School of Medicine; Professor, Department of Medicine and Department of Environmental Health Sciences; Director, National Center for Regenerative Medicine, Case Western Reserve University
• JULIE R. GRALOW, Executive Vice President and Chief Medical Officer, American Society of Clinical Oncology
• ROY S. HERBST, Ensign Professor of Medicine and Professor of Pharmacology; Director, Center for Thoracic Cancers; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science, Yale School of Medicine
• HEDVIG HRICAK, Chair, Department of Radiology, Memorial Sloan Kettering Cancer Center
• CHANITA HUGHES-HALBERT, Vice Chair for Research and Professor, Department of Preventive Medicine, Associate Director for Cancer Equity, Norris Comprehensive Cancer Center, University of Southern California
• MIMI HUIZINGA, Vice President and Head, U.S. Oncology Medical, Novartis Oncology
• ROY A. JENSEN, Director, The University of Kansas Cancer Center; William R. Jewell, M.D. Distinguished Masonic Professor, Kansas Masonic Cancer Research Institute; and Immediate Past President, Association of American Cancer Institutes
• RANDY A. JONES, Professor of Nursing, Robert Wood Johnson Foundation Nurse Faculty Scholar Alumnus, University of Virginia School of Nursing
• BETH Y. KARLAN, Vice Chair, Women's Health Research Professor, Department of Obstetrics and Gynecology, David Geffen School of Medicine; and Director, Cancer Population Genetics, Jonsson Comprehensive Cancer Center, University of California, Los Angeles
• SAMIR N. KHLEIF, Director, Jeannie and Tony Loop ImmunoOncology Lab; and Biomedical Scholar and Professor of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
• MIA LEVY, Sheba Foundation Director, Rush University Cancer Center; Associate Professor of Medicine, Division of Hematology and Oncology; and System Vice President, Cancer Services, Rush System for Health
• SCOTT M. LIPPMAN, Director, Moores Cancer Center; Distinguished Professor of Medicine, Senior Associate Dean, and Associate Vice Chancellor for Cancer Research and Care, and Chugai Pharmaceutical Chair in Cancer, University of California, San Diego
• NEAL J. MEROPOL, Vice President and Head of Medical and Scientific Affairs, Flatiron Health; and Adjunct Professor, Case Comprehensive Cancer Center
• LARISSA NEKHLYUDOV, Professor of Medicine, Harvard Medical School; Internist, Brigham and Women's Hospital; and Clinical Director, Internal Medicine for Cancer Survivors, Dana-Farber Cancer Institute
• RANDALL A. OYER, Medical Director, Oncology, Ann B. Barshinger Cancer Institute; Medical Director, Cancer Risk Evaluation Program, Penn Medicine Lancaster General Health; and President, Association of Community Cancer Centers
• CLEO A. SAMUEL-RYALS, Associate Professor of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
• RICHARD L. SCHILSKY, Principal Investigator, American Society of Clinical Oncology Targeted Agent and Profiling Utilization Registry (TAPUR^TM) Study; and Professor Emeritus, University of Chicago
• JULIE SCHNEIDER, Associate Director, Research Strategy and Partnership, Oncology Center of Excellence, Food and Drug Administration
• SUSAN M. SCHNEIDER, Associate Professor, Emerita, Duke University School of Nursing
• LAWRENCE N. SHULMAN, Professor of Medicine, Deputy Director for Clinical Services, and Director, Center for Global Cancer Medicine, Abramson Cancer Center, University of Pennsylvania
• LARA STRAWBRIDGE, Director, Division of Ambulatory Payment Models, Patient Care Models Group, Center for Medicare & Medicaid Innovation, Centers for Medicare & Medicaid Services
• GEORGE J. WEINER, C.E. Block Chair of Cancer Research, Professor of Internal Medicine and Pharmaceutical Science, and Director, Holden Comprehensive Cancer Center, The University of Iowa
• ROBERT A. WINN, Director, Massey Cancer Center; Senior Associate Dean for Cancer Innovation; Professor, Pulmonary Disease and Critical Care Medicine; and Lipman Chair in Oncology, School of Medicine, Virginia Commonwealth University
• PHYLICIA L. WOODS, Executive Director, Cancer Policy Institute, Cancer Support Community

Footnotes

1

The National Academies of Sciences, Engineering, and Medicine's forums and roundtables do not issue, review, or approve individual documents. The responsibility for the published Proceedings of a Workshop rests with the workshop rapporteurs and the institution.